EUVIMEDEUVIMED entdecken
Open Access

Delta-like Ligand 3Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models

Tran T Hoang, David Bauer, Aidan Ingham, Ileana C Miranda, Lukas M Carter, Alexa Michel, Roberto De Gregorio, Juliana Welk, Hong Zhong, John T Poirier, Michael J Morris, Lisa Bodei und 3 weitere

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.271302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Tran T Hoang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York. Hauptthemen laut MEDLINE: Radioimmunotherapy, Lung Neoplasms, Prostatic Neoplasms, Actinium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This work evaluated the in vivo performance of an anti-delta-like ligand 3 (DLL3) monoclonal antibody, TDI-Y-010, covalently linked to the MACROPA-derived chelator (mcp) for 225Ac radioimmunotherapy in 2 DLL3-positive neuroendocrine cancer models of the lung and prostate.

Methods

Ex vivo biodistribution studies were conducted to evaluate the uptake of [225Ac]Ac-mcp-TDI-Y-010 and determine appropriate therapeutic dosing. On the basis of dosimetry data, 3 doses of [225Ac]Ac-mcp-TDI-Y-010 (9.25, 18.5, and 37.0 kBq) were evaluated in female nude mice bearing Lu149 small cell lung cancer patient-derived xenografts. An additional therapeutic efficacy study was conducted in male nude mice bearing H660 neuroendocrine prostate cancer xenografts, with administered doses of 4.63, 9.25, and 18.5 kBq.

Results

In the Lu149 model, the median survival of the [225Ac]Ac-mcp-TDI-Y-010 treatment groups was significantly longer than that of the saline treatment cohorts (P < 0.0001 and P = 0.0002, respectively). In the neuroendocrine prostate cancer model, median survival was significantly longer for mice in the [225Ac]Ac-mcp-TDI-Y-010 groups than in those treated with [225Ac]Ac-mcp-IgG4 (median survival, 37 d; P = 0.002, 0.0001, and 0.0006 for the 4.63-, 9.25-, and 18.5-kBq [225Ac]Ac-mcp-TDI-Y-010 groups, respectively). Hematologic toxicity was transient in both models and comparable across all cohorts. Histopathologic assessment of background organs demonstrated mild to moderate kidney and ovary toxicity in the SC16 group compared with the highest-dose TDI-Y-010 cohort (37.0 kBq). Conclusion: [225Ac]Ac-mcp-TDI-Y-010 exhibited excellent antitumor efficacy with mild and transient hematologic toxicity, supporting its potential as a radioimmunotherapeutic agent for patients with DLL3-expressing neuroendocrine cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadioimmunotherapyLung NeoplasmsProstatic NeoplasmsActiniumAntibodies, MonoclonalNeuroendocrine TumorsAnimalsMaleMiceFemaleHumansMice, NudeCell Line, TumorTissue DistributionXenograft Model Antitumor AssaysMembrane ProteinsIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

225AcDLL3neuroendocrine cancerradioimmunotherapyradionuclide therapy

Substanzen

ActiniumDLL3 protein, humanAntibodies, MonoclonalActinium-225Membrane ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York.
  • Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, New York.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Perlmutter Cancer Center, New York University Langone Health, New York, New York; and.

Förderung

  • NCI NIH HHS

Zitieren

APA

Hoang, T. T., Bauer, D., Ingham, A., Miranda, I. C., Carter, L. M., Michel, A., De Gregorio, R., Welk, J., Zhong, H., Poirier, J. T., Morris, M. J., Bodei, L., Rudin, C. M., Tendler, S., & Lewis, J. S. (2026). Delta-like Ligand 3Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271302

Vancouver

Hoang TT, Bauer D, Ingham A, Miranda IC, Carter LM, Michel A, et al. Delta-like Ligand 3Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271302

BibTeX
@article{Hoang2026,
  author = {Hoang, Tran T and Bauer, David and Ingham, Aidan and Miranda, Ileana C and Carter, Lukas M and Michel, Alexa and De Gregorio, Roberto and Welk, Juliana and Zhong, Hong and Poirier, John T and Morris, Michael J and Bodei, Lisa and Rudin, Charles M and Tendler, Salomon and Lewis, Jason S},
  title = {Delta-like Ligand 3Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.271302}
}
Kostenlos starten →